Oxiracetam
Oxiracetam fits logical-work and mild stimulant experiments, with historical dosing around 800-2,400 mg/day and evidence led by Copani 1992 AMPA-receptor work. The practical problem is that healthy-user cognitive data and sourcing quality remain weak.
Oxiracetam scored 5.0 / 10 (⚖️ Neutral) on the BioHarmony scale as a Substance → Racetam.
What It Is
Oxiracetam scores 5.0/10 because its strongest case is cognitive and memory-oriented racetam pharmacology, with weaker support outside that lane. The best read is practical and narrow: match the intervention to users comparing racetam candidates for cognition while accepting limited direct trial support.
The main evidence anchor is Copani et al. 1992. Flicker and Grimley Evans 2001 adds important context, while Malykh and Sadaie 2010 helps define the safety, sourcing, or regulatory caveat that keeps the score from moving higher.
The key caveat is that the evidence leans on mechanism and adjacent piracetam literature more than modern outcomes in healthy adults. This report treats Oxiracetam as a candidate for specific use cases, not a general wellness shortcut.
Terminology
AMPA: A glutamate receptor family involved in fast excitatory signaling. - CYP1A2: A liver enzyme relevant to caffeine and xanthine metabolism. - ER Stress: Endoplasmic-reticulum stress, a cellular protein-folding stress pathway. - MAO-B: Monoamine oxidase B, an enzyme that breaks down dopamine-related monoamines. - NOAEL: No observed adverse effect level in toxicology work.
UDCA: Ursodeoxycholic acid, the unconjugated parent bile acid of TUDCA. - WADA: World Anti-Doping Agency, relevant for athlete prohibited-list risk.
Dosing & Protocols
Dosing information is summarized from published research and community reports. This is not a prescribing guide. Consult a healthcare provider before starting any protocol.
Routes & Forms
| Route | Form | Clinical Range | Community Range |
|---|---|---|---|
| Oral | Capsule, powder, tablet, or food form depending on intervention | 800-2,400 mg/day in historical clinical and anecdotal contexts | 800-2,400 mg/day in historical clinical and anecdotal contexts |
Protocols
Conservative research comparison Mixed
- Dose
- 800-2,400 mg
- Frequency
- As studied or label-directed, with outcome tracking
- Duration
- Single session to 12 weeks depending on endpoint
Research-assistance framing only; avoid unsupervised escalation.
How this score is calculated →
Upside contribution: 1.01
| Dimension | Weight | Score | Visual | Weighted |
|---|---|---|---|---|
| Efficacy | 25% | 2.0 | 0.500 | |
| Breadth of Benefits | 15% | 2.1 | 0.315 | |
| Evidence Quality | 25% | 1.7 | 0.425 | |
| Speed of Onset | 10% | 2.7 | 0.270 | |
| Durability | 10% | 1.8 | 0.180 | |
| Bioindividuality Upside | 15% | 2.1 | 0.315 | |
| Total | 2.005 |
Upside Rationale
Oxiracetam scores 5.0/10 because its upside is concentrated in cognitive and memory-oriented racetam pharmacology. The clearest anchor is AMPA-receptor modulation work and racetam-family clinical reviews, so the rating rewards the specific use cases while staying conservative about claims beyond them.
Efficacy (2.9/5.0): Oxiracetam earns this efficacy score because the best signals map to cognitive and memory-oriented racetam pharmacology. Copani et al. 1992 is the main anchor, while Flicker and Grimley Evans 2001 helps define where the signal remains preliminary.
Breadth of Benefits (2.1/5.0): Oxiracetam has limited breadth outside its core lane. The report gives more credit where the evidence matches users comparing racetam candidates for cognition while accepting limited direct trial support, and less where endpoints drift into unrelated systems.
Evidence Quality (2.1/5.0): Oxiracetam evidence quality is constrained by sample size, age of the literature, sponsor concentration, or indirect endpoints. Copani et al. 1992 and Malykh and Sadaie 2010 keep the score useful without overstating certainty.
Speed of Onset (3.4/5.0): Oxiracetam can produce faster feedback when the intended effect is acute attention, energy, sleep timing, digestion, or performance. That speed helps users judge fit, but it does not replace longer safety follow-up.
Durability (2.1/5.0): Oxiracetam durability is moderate to low when continued dosing, training context, sleep timing, diet, or supply quality drives the result. The score rises only when the benefit can be maintained without chasing dose escalation.
Bioindividuality Upside (2.3/5.0): Oxiracetam has meaningful bioindividuality because baseline need, medications, caffeine response, training status, liver or bile context, sleep pressure, and tolerance can change the outcome. Flicker and Grimley Evans 2001 is useful for defining that context.
Downside contribution: 1.04 (safety risks weighted extra)
| Dimension | Weight | Score | Visual | Weighted |
|---|---|---|---|---|
| Safety Risk | 30% | 1.9 | 0.570 | |
| Side Effect Profile | 15% | 1.8 | 0.270 | |
| Financial Cost | 5% | 2.8 | 0.140 | |
| Time/Effort Burden | 5% | 2.0 | 0.100 | |
| Opportunity Cost | 5% | 2.5 | 0.125 | |
| Dependency / Withdrawal | 15% | 1.5 | 0.225 | |
| Reversibility | 25% | 1.5 | 0.375 | |
| Total | 1.805 | |||
| Harm subtotal × 1.4 | 2.016 | |||
| Opportunity subtotal × 1.0 | 0.365 | |||
| Combined downside | 2.381 | |||
| Baseline offset (constant) | −1.340 | |||
| Effective downside penalty | 1.041 |
Downside Rationale
Oxiracetam downside is driven by the evidence leans on mechanism and adjacent piracetam literature more than modern outcomes in healthy adults. The risk score is highest where user selection, product quality, stimulant load, medical context, or regulation can change the expected result.
Safety (2.3/5.0): Oxiracetam safety concerns are manageable for some users and unacceptable for others depending on dose, diagnosis, medication use, and source quality. Flicker and Grimley Evans 2001 is the main safety anchor for this dimension.
Side Effects (2.3/5.0): Oxiracetam side effects matter because the likely use cases often depend on subjective feel, stimulation, digestion, sleep, or skin response. Copani et al. 1992 helps frame expected benefits against tolerability.
Interaction Risk (2.1/5.0): Oxiracetam interaction risk rises when users combine it with stimulants, sedatives, anticoagulants, liver-active agents, training stress, or disease-specific treatment. The report keeps this dimension separate from general safety.
Supply (2.8/5.0): Oxiracetam supply risk reflects labeling accuracy, adulteration, ingredient identity, and whether the market is supplement, prescription, peptide, or gray-market dominated. Malykh and Sadaie 2010 is especially relevant when product trust is part of the risk.
Cost (2.1/5.0): Oxiracetam cost risk is not only price per serving. It also includes the cost of chasing weak evidence, lab testing, medical monitoring, or replacing simpler options such as sleep, diet, training, or caffeine management.
Regulatory (2.5/5.0): Oxiracetam regulatory risk depends on whether the compound is a normal food, a dietary supplement ingredient, a drug, a sport-restricted substance, or a research peptide. This can be the deciding downside for athletes and cautious users.
Bioindividuality Downside (2.4/5.0): Oxiracetam bioindividuality downside is meaningful because personal risk can swing with anxiety, sleep timing, pregnancy, age, liver or kidney status, sport testing, CYP metabolism, and baseline deficiency or excess.
Verdict
Oxiracetam is a conditional research candidate rather than a universal recommendation. The score is most favorable when the reader's target matches the highest use-case scores, the product source is credible, and the reader can track a concrete outcome before and after use. The score is least favorable when Oxiracetam is used to chase vague optimization, replace higher-certainty basics, or stack with overlapping compounds without a clear reason.
✅ Best for: Occasional logical-work experiments where sourcing constraints and weak modern replication are acceptable. Oxiracetam makes the most sense when the reader can define the target outcome in advance, compare Oxiracetam with the related reports above, and stop quickly if the result is poor.
❌ Avoid if: Avoid Oxiracetam when legal status, athlete testing, medication conflicts, allergy risk, organ disease, pregnancy questions, stimulant sensitivity, or poor sourcing changes the risk picture. Avoid using Oxiracetam as a substitute for sleep, nutrition, training, medical care, or well-supported alternatives.
Use Case Breakdown
The overall BioHarmony score reflects the intervention's primary evidence profile. These subratings are independent assessments per use case.
Cognition / Focus: 5.0/10
Score: 5.0/10Oxiracetam scores 5.0/10 for cognition focus because the human or mechanistic literature points most directly at attention, focus, or cognitive-task performance. The strongest support comes from Copani A. et al. 1992, but the practical rating stays bounded by study size, replication, and how directly the endpoint maps to healthy-user goals. For readers, Oxiracetam is best interpreted as a focused use-case candidate, not a broad proof of benefit across unrelated systems. The score would move higher with independent replication, longer follow-up, and cleaner head-to-head comparisons against common alternatives.
Memory: 5.0/10
Score: 5.0/10Oxiracetam scores 5.0/10 for memory because the most relevant studies involve memory tasks, cognitive impairment, or working-memory endpoints. The strongest support comes from Copani A. et al. 1992, but the practical rating stays bounded by study size, replication, and how directly the endpoint maps to healthy-user goals. For readers, Oxiracetam is best interpreted as a focused use-case candidate, not a broad proof of benefit across unrelated systems. The score would move higher with independent replication, longer follow-up, and cleaner head-to-head comparisons against common alternatives.
Energy / Fatigue: 5.0/10
Score: 5.0/10Oxiracetam scores 5.0/10 for energy because the most plausible benefit is acute perceived energy or stimulant-like activation. The strongest support comes from Copani A. et al. 1992, but the practical rating stays bounded by study size, replication, and how directly the endpoint maps to healthy-user goals. For readers, Oxiracetam is best interpreted as a focused use-case candidate, not a broad proof of benefit across unrelated systems. The score would move higher with independent replication, longer follow-up, and cleaner head-to-head comparisons against common alternatives.
Frequently Asked Questions
What does Oxiracetam actually do?
Oxiracetam mainly acts through the biology described in this report, and the best concise source is Copani A. et al. 1992. Oxiracetam should be read as a research-assistance topic rather than a treatment recommendation. That is why the score separates plausible pathways from proven user value.
How much Oxiracetam is typically used?
Oxiracetam is usually discussed around 800-2,400 mg/day in historical clinical and anecdotal contexts, but dosing depends on context, product quality, and clinician constraints. This report lists research and anecdotal ranges for comparison only. Oxiracetam should not be stacked casually with overlapping drugs or stimulants, and higher doses should be treated as a separate risk decision. The safest reading is to compare published ranges with the label and personal tolerance.
What does the human evidence show for Oxiracetam?
Oxiracetam has an evidence profile led by Copani A. et al. 1992 and the other sources in the evidence table. Oxiracetam receives credit when human outcomes exist and loses credit when the work is small, industry-concentrated, disease-specific, or not independently replicated. That is why a popular community use can still receive a modest score when the direct clinical literature is thin.
Is Oxiracetam safe long term?
Oxiracetam looks safer when dose, source quality, medication conflicts, and stop criteria are handled conservatively. The long-term safety answer is weaker when human follow-up is short, when products are unapproved drugs, or when stimulant effects can affect sleep and cardiovascular comfort. Oxiracetam earns a better safety rating only where the evidence base includes ordinary-use tolerability and clear reversibility.
Who should avoid Oxiracetam?
Oxiracetam should be avoided by readers with relevant medication conflicts, pregnancy questions, severe organ disease, allergy risk, or athlete testing exposure when those concerns apply. Oxiracetam also deserves caution when the supply chain is unclear or when the main goal could be met by better-studied options. The report frames these as research guardrails, not individualized medical instructions.
How fast does Oxiracetam work?
Oxiracetam may feel acute when the mechanism is stimulant-like, but disease or recovery outcomes usually need longer observation. The timeline in this report separates same-day subjective effects from delayed biomarkers and functional changes. Oxiracetam should be judged with a preplanned outcome, because vague improvement tracking can make short-lived arousal feel more useful than it is.
How is Oxiracetam different from nearby alternatives?
Oxiracetam differs from nearby alternatives by mechanism, evidence quality, legality, and product reliability. The related reports linked in the verdict help compare Oxiracetam with better-known options before treating the category as interchangeable. A close alternative may have lower subjective novelty but better replication, easier sourcing, or fewer interaction problems, which matters for the final score.
What would make the Oxiracetam score change?
Oxiracetam would score higher with larger independent trials, longer safety follow-up, clearer dosing, and direct evidence for the main use cases. Oxiracetam would score lower if safety signals strengthen, product quality worsens, or better alternatives cover the same goal with less uncertainty. The score is therefore a snapshot of current evidence, not a permanent verdict.
How This Score Could Change
BioHarmony scores are living assessments. New research, regulatory changes, or personal context can shift the score up or down. These are the most likely scenarios that would change this intervention's rating.
Oxiracetam could move meaningfully if the evidence base changes because several current uncertainties are fixable. Independent trials could raise confidence, longer follow-up could clarify safety, and better product testing could reduce sourcing concern. Oxiracetam could also fall if larger studies fail to replicate the small positive findings, if regulatory scrutiny increases, or if real-world users report a pattern of sleep, mood, digestive, or cardiovascular problems. The scenarios below show how the same intervention can move across tiers without changing the scoring method, simply by improving or weakening the underlying facts.
| Scenario | Likely score |
|---|---|
| Larger independent human trials replicate the best outcome and safety stays clean. | 6.2 / 10 👍 Worth trying |
| Evidence stays mostly small, sponsor-linked, or disease-specific. | 5.0 / 10 ⚖️ Neutral |
| New safety, sourcing, regulatory, or replication concerns appear. | 3.8 / 10 ⚠️ Caution |
BioHarmony Engine v1.0
Key Evidence Sources
- Nootropic drugs positively modulate alpha-amino-3-hydroxy-5-methyl-4-isoxazolepropionic acid-sensitive glutamate receptors in neuronal cultures. Nootropic drugs positively modulate alpha-amino-3-hydroxy-5-methyl-4-isoxazolepropionic acid-sensitive glutamate receptors in neuronal cultu
- Piracetam for dementia or cognitive impairment. Reviewed in 2026 for study design and population fit; supports a specific endpoint rather than broad wellness claims.
- Piracetam: a review of pharmacological properties and clinical uses. Reviewed in 2026 as clinical or mechanistic background; sample, year, and endpoint directness shape the confidence rating.
- Wikidata entity Q422993. Reviewed in 2026 for citation integrity; useful for mechanism or outcome context but not treated as universal proof.
- Dietary Supplements. Reviewed in 2026 as a primary evidence source; study design, year, and endpoint context are used to bound the report claim.
- ClinicalTrials registry. Reviewed in 2026 for study design and population fit; supports a specific endpoint rather than broad wellness claims.
- PubChem compound database. Reviewed in 2026 as clinical or mechanistic background; sample, year, and endpoint directness shape the confidence rating.
- World Anti-Doping Agency prohibited list. Reviewed in 2026 for citation integrity; useful for mechanism or outcome context but not treated as universal proof.
- NIH Office of Dietary Supplements. Reviewed in 2026 as a primary evidence source; study design, year, and endpoint context are used to bound the report claim.
- MedlinePlus herbs and supplements. Reviewed in 2026 for study design and population fit; supports a specific endpoint rather than broad wellness claims.
Holistic Evidence Profile
Evidence on this intervention is summarized across three complementary streams: contemporary clinical research, pre-RCT-era pharmacology and observational use, and the traditional medical systems that documented it first. Convergence across streams signals higher confidence; divergence is surfaced honestly.
Modern Clinical Research
Confidence: Low
Citations: Copani 1992: Nootropic drugs positively modulate alpha-amino-3-hydroxy-5-methyl-4-isoxazolepropionic acid-sensitive glutamate receptors in neuronal cultures.
Pre-RCT-Era Pharmacology and Use
Citations: Nootropic drugs positively modulate alpha-amino-3-hydroxy-5-methyl-..., Piracetam for dementia or cognitive impairment, PMID 20166767
Traditional Medicine Systems
Citations: Nootropic drugs positively modulate alpha-amino-3-hydroxy-5-methyl-..., Piracetam for dementia or cognitive impairment, PMID 20166767
What to Track If You Try This
These are the data points that matter most while running a 30-day Experiment with this intervention.
How to read this section
- Pre
- Test or score before starting the protocol. Anchors a baseline.
- During
- Track while running the protocol so you can see if anything is changing.
- Post
- Re-test after a full cycle to confirm the change held.
- Up
- The marker should rise. For most positive outcomes, that is a good sign.
- Down
- The marker should fall. For most positive outcomes, that is a good sign.
- Stable
- The marker should hold steady. Big swings in either direction are a yellow flag.
- Watch
- Direction depends on dose, timing, and your baseline. Pay close attention to the trend.
- N/A
- No expected direction. The entry is there to anchor a baseline reading.
- Primary
- The Pulse dimension most likely to shift. Track this first.
- Secondary
- Also relevant, but a smaller or less consistent shift. Track if Primary is unclear.
Bloodwork to Order
Open These Markers In Your Dashboard
- Blood Pressure Baseline (pre-protocol)
- Sleep Duration During | Expected Watch
Pulse Dimensions to Watch
- Drive During | Expected Up | Primary
- Energy During | Expected Up | Secondary
- Sleep During | Expected Watch | Secondary
Subjective Signals (Daily Voice Card)
- Logical Work Quality Scale 1-5 | During | Expected Up
- Headache Scale 1-5 | During | Expected Watch
Red Flags: Stop and Consult
- Severe headache, agitation, or insomnia
- Product sourcing uncertainty
Other interventions for Cognition & Focus
See all ratings →📊 How BioHarmony scoring works
BioHarmony translates a weighted expected-value calculation into a reader-facing 0–10 score. Tier bands: Skip 0–3.6, Caution 3.7–4.7, Neutral 4.8–5.7, Worth Trying 5.8–6.9, Strong Recommend 7.0–7.9, Top-tier 8.0+.
Harm-type downsides (safety risk, side effects, reversibility, dependency) carry a 1.4× precautionary multiplier. Harm weighs more than benefit. Opportunity-type downsides (financial cost, time/effort, opportunity cost) are subtracted at face value.
Use case subratings are independent assessments of how well the intervention addresses specific health goals. They are not components of the overall score. Each subrating reflects the scorer's judgment based on use-case-specific evidence, safety, and effect sizes.
Every dimension is evaluated on a 1–5 scale, and the baseline (1) is subtracted before weighting. A perfect intervention with zero downsides contributes zero penalty rather than a residual floor, so top-tier scores are actually reachable.
EV = Upside − Downside
EV = 1.005 − 1.041 = -0.036
Formula v0.5 maps EV = 0 to score 5.0. Above neutral, 1 EV point equals 1 score point. Below neutral, 1 EV point equals about 0.71 score points, so EV = −7 reaches 0.0 while EV = +5 reaches 10.0. Both sides use the full 5-point half-scale.
Score = 5 + (-0.036 / 7) × 5 = 5.0 / 10
Further learning
65+ Nootropic Ingredients I’ve Supplemented (Rated & Reviewed)
I've tested all kinds of nootropic ingredients & brain-boosting supplements. Here's a simple rundown, my personal ratings and mini review, and practical uses of…
Unconventional Ways to Power Up Your Brain & Perform Like an Elite Athlete
Did you know you could optimize your brain & body performance using nootropics safely & effectively? We discuss using substances like caffeine, dynamine &…
